In neurodegenerative diseases, TMAO penetrates the BBB, impairing synaptic plasticity through PERK activation or mTOR pathway inhibition (Zhou et al., 2023), while promoting Aβ and tau protein aggregation in Alzheimer’s and Parkinson’s disease progression. Here, MTOR is linked to Parkinson disease.